Tri-Point planning October IDE submission for Traumaseal wound closure adhesive.
This article was originally published in The Gray Sheet
Executive Summary
TRI-POINT IDE FOR TRAUMASEAL WOUND CLOSURE ADHESIVE is slated for submission to FDA in late October, the company says. Privately held Tri-Point hopes to begin clinical trials in January 1996 for Traumaseal, a cyanoacrylate for use in place of sutures to close topical wounds from skin lacerations, minimally invasive surgery, and plastic surgery.